The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 82, Issue 2-3, 2010, Pages 87-95

  Block, R C ^a   Duff, R ^a   Lawrence, P ^b   Kakinami, L ^a   Brenna, J T ^b   Shearer, G C ^c   Meednu, N ^a   Mousa, S ^d   Friedman, A ^a   Harris, W S ^c   Larson, Mark ^e   Georas, S ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c SANFORD RESEARCH   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e AUGUSTANA COLLEGE   (United States)

Author keywords

Autotaxin; Docosahexaenoic acid; Eicosapentaenoic acid; Lysophosphatidic acid; Lysophosphatidylcholine; Lysophospholipase D

Indexed keywords

ACETYLSALICYLIC ACID; AUTOTAXIN; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYDROLYSIS; INGESTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

ADULT; ASPIRIN; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ENZYME ACTIVATION; FEMALE; HUMANS; LIPID METABOLISM; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; PHOSPHODIESTERASE I; PYROPHOSPHATASES; YOUNG ADULT;

EID: 77951634698     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2009.12.005     Document Type: Article

References (47)

1. Aoki J. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 2004, 15:477-489.
2. Wu W.T., Chen C.N., Lin C.I., Chen J.H., Lee H. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 2005, 146:3387-3400.
3. Lucas A., Grynberg A., Lacour B., Goirand F. Dietary n-3 polyunsaturated fatty acids and endothelium dysfunction induced by lysophosphatidylcholine in Syrian hamster aorta. Metabolism 2008, 57:233-240.
4. Panchatcharam M., Miriyala S., Yang F., Rojas M., End C., Vallant C., et al. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 2008, 103:662-670.
5. G. Schmitz, K. Ruebsaamen, Metabolism and atherogenic disease association of lysophosphatidylcholine, Atherosclerosis (2009).
6. Chen G., Li J., Qiang X., Czura C.J., Ochani M., Ochani K., et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J. Lipid Res. 2005, 46:623-627.
7. Yan J.J., Jung J.S., Lee J.E., Lee J., Huh S.O., Kim H.S., et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat. Med. 2004, 10:161-167.
8. Aoki J., Inoue A., Okudaira S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 2008, 1781:513-518.
9. Zhao Y., Natarajan V. Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal 2009, 21:367-377.
10. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 2002, 158:227-233.
11. van Meeteren L.A., Ruurs P., Stortelers C., Bouwman P., van Rooijen M.A., Pradere J.P., et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 2006, 26:5015-5022.
12. Stracke M.L., Krutzsch H.C., Unsworth E.J., Arestad A., Cioce V., Schiffmann E., et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 1992, 267:2524-2529.
13. Federico L., Pamuklar Z., Smyth S.S., Morris A.J. Therapeutic potential of autotaxin/lysophospholipase D inhibitors. Curr. Drug Targets 2008, 9:698-708.
14. Tokumura A., Harada K., Fukuzawa K., Tsukatani H. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta 1986, 875:31-38.
15. Hayashi K., Takahashi M., Nishida W., Yoshida K., Ohkawa Y., Kitabatake A., et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 2001, 89:251-258.
16. Yoshida K., Nishida W., Hayashi K., Ohkawa Y., Ogawa A., Aoki J., et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 2003, 108:1746-1752.
17. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
18. Kereiakes D.J. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation 2003, 108:III22-III27.
19. Li Z.G., Yu Z.C., Wang D.Z., Ju W.P., Zhan X., Wu Q.Z., et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol. Res. 2008, 30:366-369.
20. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 2001, 345:1809-1817.
21. Xu A.S., Ohba Y., Vida L., Labotka R.J., London R.E. Aspirin acetylation of betaLys-82 of human hemoglobin. NMR study of acetylated hemoglobin Tsurumai. Biochem. Pharmacol. 2000, 60:917-922.
22. Rendell M., Nierenberg J., Brannan C., Valentine J.L., Stephen P.M., Dodds S., et al. Inhibition of glycation of albumin and hemoglobin by acetylation in vitro and in vivo. J. Lab. Clin. Med. 1986, 108:286-293.
23. Larson M.K., Ashmore J.H., Harris K.A., Vogelaar J.L., Pottala J.V., Sprehe M., et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb. Haemost. 2008, 100:634-641.
24. Lopez-Lopez A., Castellote-Bargalló A., López-Sabater M. Comparison of two direct methods for the determination of fatty acids in human milk. Chromatographia 2006, 54:743-747.
25. Yoon H.R., Kim H., Cho S.H. Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 2003, 788:85-92.
26. Zhao Z., Xiao Y., Elson P., Tan H., Plummer S.J., Berk M., et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Oncol. 2007, 25:2696-2701.
27. Zhao Z., Xu Y. Measurement of endogenous lysophosphatidic acid by ESI-MS/MS in plasma samples requires pre-separation of lysophosphatidylcholine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:3739-3742.
28. Ferguson C.G., Bigman C.S., Richardson R.D., van Meeteren L.A., Moolenaar W.H., Prestwich G.D. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org. Lett. 2006, 8:2023-2026.
29. Hosogaya S., Yatomi Y., Nakamura K., Ohkawa R., Okubo S., Yokota H., et al. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann. Clin. Biochem. 2008, 45:364-368.
30. Cohen J.T., Bellinger D.C., Connor W.E., Kris-Etherton P.M., Lawrence R.S., Savitz D.A., et al. A quantitative risk-benefit analysis of changes in population fish consumption. American Journal of Preventive Medicine 2005, 29:325-334.
31. American Heart Association Nutrition Committee, Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006, 114:82-96.
32. Lemaitre R.N., King I.B., Mozaffarian D., Sotoodehnia N., Rea T.D., Kuller L.H., et al. Plasma phospholipid trans fatty acids, fatal ischemic heart disease, and sudden cardiac death in older adults: the cardiovascular health study. Circulation 2006, 114:209-215.
33. Raitt M.H., Connor W.E., Morris C., Kron J., Halperin B., Chugh S.S., et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: A randomized controlled trial. JAMA 2005, 293:2884-2891.
34. Leaf A., Albert C.M., Josephson M., Steinhaus D., Kluger J., Kang J.X., et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005, 112:2762-2768.
35. Brouwer I.A., Zock P.L., Camm A.J., Bocker D., Hauer R.N.W., Wever E.F.D., et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: The Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) Randomized Trial. JAMA 2006, 295:2613-2619.
36. M. Lagarde, N. Bernoud, N. Brossard, D. Lemaitre-Delaunay, F. Thies, M. Croset, et al., Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain, J. Mol. Neurosci. 16 (2001) 201-204; discussion 215-21.
37. K. Fekete, T. Marosvolgyi, V. Jakobik, T. Decsi, Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans: a systematic review, Am. J. Clin. Nutr. (2009).
38. Tomsig J.L., Snyder A.H., Berdyshev E.V., Skobeleva A., Mataya C., Natarajan V., et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 2009, 419:611-618.
39. Masuda A., Nakamura K., Izutsu K., Igarashi K., Ohkawa R., Jona M., et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br. J. Haematol. 2008, 143:60-70.
40. Prestwich G.D., Gajewiak J., Zhang H., Xu X., Yang G., Serban M. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim. Biophys. Acta 1781, 2008:588-594.
41. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
42. Dona M., Fredman G., Schwab J.M., Chiang N., Arita M., Goodarzi A., et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 2008, 112:848-855.
43. Harris W.S. Expert opinion: omega-3 fatty acids and bleeding-cause for concern?. Am. J. Cardiol. 2007, 99:44C-46C.
44. Chiang N., Hurwitz S., Ridker P.M., Serhan C.N. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol. 2006, 26:e14-e17.
45. Harris W.S., von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev. Med. 2004, 39:212-220.
46. Harris W.S., Sands S.A., Windsor S.L., Ali H.A., Stevens T.L., Magalski A., et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 2004, 110:1645-1649.
47. Patrono C., Garcia Rodriguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 2005, 353:2373-2383.